Fehrenbach Heinz, Fehrenbach Antonia, Dietzel Erik, Tschernig Thomas, Krug Norbert, Grau Veronika, Hohlfeld Jens M
Clinical Research Group "Chronic Airway Diseases", Clinic of Internal Medicine (Respiratory Medicine), Philipps-University Marburg, Baldingerstrasse, Marburg Germany.
Anat Rec (Hoboken). 2007 Aug;290(8):974-80. doi: 10.1002/ar.20549.
Quantitative (immuno) transmission electron microscopy using design-based stereology was performed on specimens collected by means of systematic uniform random sampling of rat lungs, which were fixed by vascular perfusion to stabilize intra-alveolar surfactant in situ. This procedure ensures that the data recorded are representative of the whole organ. Ultrathin sections of specimens embedded at low temperature in Lowicryl HM20 were labeled by indirect immuno-gold staining for surfactant protein A. We observed that, 3 days after treatment of lungs in vivo with truncated keratinocyte growth factor (DeltaN23-KGF), a potent mitogen of alveolar epithelial type II cells, surfactant protein A associated with the tubular myelin fraction of intra-alveolar surfactant was increased by 47% in comparison with buffer-treated control lungs. Despite the marked type II cell hyperplasia, the relative amount of ultrastructural surfactant subtypes was not significantly affected. Because surfactant protein A reduces the sensitivity to inhibition of the biophysical activity of surfactant by exudating plasma proteins, we propose that pretreatment of lungs with DeltaN23-KGF ameliorates adverse effects observed in acute lung injury following, for example, ischemia and reperfusion.
采用基于设计的体视学方法进行定量(免疫)透射电子显微镜检查,样本通过对大鼠肺进行系统均匀随机抽样采集,经血管灌注固定以原位稳定肺泡表面活性物质。该程序确保记录的数据能代表整个器官。将样本在低温下包埋于Lowicryl HM20中制成超薄切片,通过间接免疫金染色标记表面活性蛋白A。我们观察到,在用截短的角质形成细胞生长因子(DeltaN23-KGF,一种肺泡II型上皮细胞的有效促有丝分裂原)对肺进行体内治疗3天后,与经缓冲液处理的对照肺相比,与肺泡表面活性物质的管状髓鞘部分相关的表面活性蛋白A增加了47%。尽管II型细胞明显增生,但超微结构表面活性物质亚型的相对量未受到显著影响。由于表面活性蛋白A可降低血浆蛋白渗出对表面活性物质生物物理活性抑制的敏感性,我们提出用DeltaN23-KGF预处理肺可改善例如缺血再灌注后急性肺损伤中观察到的不良反应。